INTERCEPT Safety Evaluation in Anemic Patients

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2019

Primary Completion Date

March 31, 2020

Study Completion Date

June 30, 2020

Conditions
Anemia
Interventions
DEVICE

INTERCEPT

The pathogen reduction process begins with a unit of whole blood collected according to local standards and procedures at the blood center. The blood unit is treated with amustaline and glutathione (INTERCEPT blood system for whole blood) according to manufacturer's instructions. The INTERCEPT blood system is performed on a single unit of not leuco-reduced whole blood treated with amustaline and glutathione in CPD

DEVICE

Standard of Care

The control article is Standard of Care, either RBC or whole blood collected by the Centre National de Transfusion Sanguine (CNTS), processed according to the local procedure and in compliance with quality criteria defined by the manufacture regarding the volume, hemoglobin content, hematocrit, storage temperature, age of blood and storage in the predefined anticoagulant solution.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Cerus Corporation

INDUSTRY

lead

Swiss Transfusion SRC

OTHER

NCT03486054 - INTERCEPT Safety Evaluation in Anemic Patients | Biotech Hunter | Biotech Hunter